Literature DB >> 18754966

Long-term clinical outcomes of the Drug-Eluting Stents in the Real World (DESIRE) Registry.

Amanda Sousa1, J Ribamar Costa, Adriana C Moreira, Manuel Cano, Galo Maldonado, Ricardo A Costa, Ricardo Pavanello, Edson R Romano, Cantidio Campos, Nagib Haddad, Alexandre Abizaid, Fausto Feres, Luiz Alberto Mattos, Rodolfo Staico, J Eduardo Sousa.   

Abstract

BACKGROUND: Recently, cardiologists have treated more complex patients and lesions with drug-eluting stents (DES). However, long-term efficacy and safety of the off-label use of these new devices is yet to be demonstrated.
METHODS: The Drug-Eluting Stents in the Real World (DESIRE) registry is a prospective, nonrandomized single-center registry with consecutive patients treated solely with DES between May 2002 and May 2007. The primary end-point was long-term occurrence of major adverse cardiac events (MACE). Patients were clinically evaluated at 1, 3, and 6 months and then annually up to 5 years.
RESULTS: A total of 2,084 patients (2,864 lesions and 3,120 DES) were included. The mean age was 63.8 +/- 11.5 years. Diabetes was detected in 28.9% and 40.7% presented with acute coronary syndrome. Cyphertrade mark was the predominant DES in this registry (83.5%). Mean follow-up time was 2.6 +/- 1.2 years and was obtained in 96.5% of the eligible patients. Target lesion revascularization (TLR) was performed in 3.3% of the patients. Q wave myocardial infarction (MI) occurred in only 0.7% of these patients and total stent thrombosis rate was 1.6% (n = 33). Independent predictors of thrombosis were PCI in the setting of MI (HR 11.2; 95% CI, 9.6-12.4, P = 0.001), lesion length (HR 4.6; 95% CI, 3.2-5.3, P = 0.031), moderate to severe calcification at lesion site (HR 13.1; 95% CI, 12.1-16.7, P < 0.001), and in-stent residual stenosis (HR 14.5; 95% CI, 10.2-17.6, P < 0.001).
CONCLUSION: The use of DES in unselected population is associated with long-term safety and effectiveness with acceptable low rates of adverse clinical events.

Entities:  

Mesh:

Year:  2008        PMID: 18754966     DOI: 10.1111/j.1540-8183.2008.00379.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  5 in total

1.  Long-term clinical outcomes of patients with rheumatoid arthritis and concomitant coronary artery disease.

Authors:  Marco Spartera; Cosmo Godino; Elena Baldissera; Corrado Campochiaro; Ketty La Spina; Patrizia Aiello; Anna Salerno; Michela Cera; Valeria Magni; Richard J Jabbour; Lorenzo Dagna; Moreno Tresoldi; Alberto Cappelletti; Ottavio Alfieri; Antonio Colombo; Maria Grazia Sabbadini; Alberto Margonato
Journal:  Am J Cardiovasc Dis       Date:  2017-02-15

2.  Serial angiographic and intravascular ultrasound evaluation to interrogate the presence of late "catch-up" phenomenon after Cypher® sirolimus-eluting stent implantation.

Authors:  Daniel Chamié; Alexandre Abizaid; J Ribamar Costa; Fausto Feres; J Fábio Almiro da Silva; Luiz Alberto P Mattos; Rodolfo Staico; Ricardo A Costa; Andréa Abizaid; Luiz Fernando L Tanajura; Amanda G M R Sousa; J Eduardo Sousa
Journal:  Int J Cardiovasc Imaging       Date:  2010-11-17       Impact factor: 2.357

3.  Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?

Authors:  Vasilios G Athyros; Thomas D Gossios; Konstantinos Tziomalos; Matilda Florentin; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2011-12-30       Impact factor: 3.318

4.  Long-term effectiveness and safety of sirolimus drug-eluting stents.

Authors:  Mahesh Bikkina; Jayanth Koneru
Journal:  Med Devices (Auckl)       Date:  2011-08-17

5.  Efficacy and safety of drug-eluting stents in the real world: 8-year follow-up.

Authors:  Denise Oliveira Pellegrini; Vitor Osório Gomes; Ricardo Lasevitch; Luis Smidt; Marco Aurélio Azeredo; Priscila Ledur; Rodrigo Bodanese; Leonardo Sinnott; Emílio Moriguchi; Paulo Caramori
Journal:  Arq Bras Cardiol       Date:  2014-08-01       Impact factor: 2.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.